Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL21066268 | 1.00 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL11254388 | 1.00 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21081888 | 1.00 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL4165943 | 1.00 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28464702 | 0.96 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL28168255 | 0.92 | LMNA (0.71) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL23066399 | 0.92 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2477078 | 0.92 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594083 | 0.92 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2297640 | 0.92 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883504-B2 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20090155906-A1 | CELL DIFFERENTIATION SUPPRESSING AGENT, METHOD OF CULTURING CELLS USING THE SAME, CULTURE SOLUTION, AND CULTURED CELL LINE | MIYABAYASHI TOMOYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7138416-B2 | Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate | TORRENT PHARMACEUTICALS LTD. (IN) | 2006-11-21 | — | — | US | disclosed |
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-12-04 | — | — | US | disclosed |
| US-4199444-A | TREATMENT WITH PSEUDOMONAS AERUGINOSA UNDER AEROBIC CONDITIONS | SYBRON CORPORATION (US) | 1980-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A4 | LMNA 2178/4885L3MBTL1 1320/4885TDP1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.